Go to the Globe and Mail homepage

Jump to main navigationJump to main content

This file photo shows a vial of Botox, made by Allergan. (Damian Dovarganes/AP)
This file photo shows a vial of Botox, made by Allergan. (Damian Dovarganes/AP)

Allergan seeks deal with Salix to fend off Valeant: report Add to ...

Botox maker Allergan Inc. has approached Salix Pharmaceuticals Ltd. and at least one other company about a potential takeover in a bid to avert the $53-billion (U.S.) hostile takeover from Valeant Pharmaceuticals International Inc., the Wall Street Journal said.

Allergan and Salix declined to comment on the matter.

More Related to this Story

Shares of Salix, which itself is in the process of merging with a unit of Swiss-listed Cosmo Pharmaceuticals, jumped about 10 per cent on Tuesday.

It isn’t clear where any talks with Salix stand, but one of the sources said Allergan could strike a takeover deal with the company or another unknown party as early as next month, Journal said.

Raleigh, North Carolina-based Salix makes products used to prevent or treat gastrointestinal disorders. So far, it has generated sales of $766.4-million this year.

Cosmo said in July it would merge its Irish subsidiary with Salix, another example of overseas deal-making by U.S. companies seeking to lower their tax bill by shifting tax domiciles abroad.

William Ackman’s hedge fund, Pershing Square Capital Management, which owns nearly 10 per cent of Allergan, worked with Valeant to put together the takeover deal unveiled in April.

Follow us on Twitter: @GlobeBusiness

In the know

Most popular video »


More from The Globe and Mail

Most Popular Stories